Migraine News and Research

Latest Migraine News and Research

Winter weather tips for people with high blood pressure

It's sad but true. Celebrity groundhog Punxsutawney Phil of PA and his relatives accurately predict the end or extension of winter only 39 percent of the time according to the United States National Climate Center.

12 Jan 2011

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro in Germany and the UK

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).

11 Jan 2011

NovaDel receives $500,000 milestone payment from Akrimax in connection with NitroMist agreement

NovaDel Pharma Inc. today announced that it has received a $500,000 milestone payment from Akrimax Pharmaceuticals. The milestone payment was received in connection with the license and distribution agreement, dated October 27, 2009, between NovaDel Pharma Inc. and Mist Acquisition, LLC, an affiliate of Akrimax Pharmaceuticals.

7 Jan 2011

Researchers say women with multiple sclerosis have more HLA genes than men

Women who have multiple sclerosis (MS) are more likely to have a gene associated with multiple sclerosis than men with the disease and it is this gene region where environment interacts with the genetics, according to a study published in the January 5, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

6 Jan 2011

Epilepsy not getting the public attention and research funding it deserves

Epilepsy, a common and serious neurologic disorder that affects millions of people, is not getting the public attention and funding for research it deserves, according to an editorial on a study published in the January 4, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

28 Dec 2010

MigreLief releases safe, proven effective supplement for children with migraines

MigreLief, the first name in migraine prevention, releases a safe and proven effective supplement for children of all ages: Children's MigreLief.

24 Dec 2010

Zogenix announces underwriters partial exercise of over-allotment option in initial public offering

Zogenix, Inc. announced today that the underwriters of its recently completed initial public offering of common stock have partially exercised their option to purchase shares of common stock from Zogenix to cover over-allotments. The sale of additional shares is expected to close on December 27, 2010.

23 Dec 2010

Fried fish consumption may increase risk of stroke

People living in the "stroke belt" states eat more fried fish than people living in the rest of the country, which may contribute to the high rate of death from stroke in those states, according to a study published in the December 22, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Dec 2010

Spinal Botox injection reduces pain

Botulinum neurotoxin type A (BoNT/A)—better known as Botox—reduces responses to an inflammation-related pain stimulus when injected into the spinal canal in mice, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

22 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

Second brain death exam impacts organ donation rates

Requiring a second exam on a person who is considered brain dead may be unnecessary, according to a study on the impact of a second brain death exam on organ donation rates. The research is published in the December 15, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

16 Dec 2010

Majority of brain tumor patients use alternative therapies

Many people with incurable brain tumors use alternative therapies, such as taking vitamins and homeopathy, in addition to their conventional treatments, according to a study published in the December 14, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Dec 2010

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Inc. today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner at the MIP Awards Luncheon on December 10, 2010.

13 Dec 2010

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BioDelivery Sciences International, Inc. today announced the enrollment and dosing of the first patient in its Phase 3 clinical program evaluating the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

9 Dec 2010

Zogenix, Desitin receive MAA approval for SUMAVEL DosePro needle-free delivery system in Denmark

Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH ("Desitin") were granted approval of the Marketing Authorization Application ("MAA") for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system by the Danish Medicines Agency of Denmark.

7 Dec 2010

Restless legs syndrome during pregnancy may reappear later on

Women with transient restless legs syndrome (RLS) during pregnancy appear to be at a higher risk of developing a chronic form of RLS later in life or have the same symptoms during future pregnancies, according to new research published in the December 7, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology. RLS is a sleep-related motor disorder that causes an unpleasant feeling in the legs. The condition generally worsens during rest at night and improves with movement. Symptoms tend to progress with age.

7 Dec 2010

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Zogenix, Inc. and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application (MAA) for SUMAVEL® DosePro™ (sumatriptan injection) Needle-Free Delivery System. Denmark is the first country in Europe to grant marketing authorization for SUMAVEL DosePro for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.

2 Dec 2010

Physicians prescribe less pain medications for individuals evading the police

If you should find yourself running from the police, watch your step. If you fall and break an ankle, chances are you'll receive less pain medication when they take you to the ER for treatment.

1 Dec 2010

Migraine headache with aura increases risk of stroke among women: Research

Women with a history of migraine headache with aura (transient neurological symptoms, mostly visual impairments) are at increased risk of stroke. However, according to new research reported in Circulation: Journal of the American Heart Association stroke events in women with migraine with aura are more likely to have mild or no disability compared to those without migraine.

1 Dec 2010

Data on UCB’s anti-epileptic drugs to be presented at AES annual meeting

New data on UCB's anti-epileptic drug (AED) Vimpat (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking place at the San Antonio Convention Center in San Antonio, Texas from December 3 to 7, 2010. Data will also be presented on Keppra XR and the investigative epilepsy therapy, brivaracetam.

1 Dec 2010